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Abstract 
Salvage and de novo purine and pyrimidine nucleotide syntheses were studied in H 9 (a human lymphoid cell line) and H9_AZ T cells 
(chronically zidovudine-exposed H 9 cells). H9.AZ T cells incorporated 18% and 27% more hypoxanthine and uridine, respectively, than H 9 
cells. The incorporation of the formate and bicarbonate was similar in both cell lines. Purine and pyrimidine de novo synthesis was 
inhibited by hypoxanthine and uridine, respectively. Hypoxanthine and uridine salvage pathways, however, were not affected by formate 
or bicarbonate. Short-term AZT exposure of cells had no effect on nucleotide synthesis. Some of the problems encountered in the studies 
of purine and pyrimidine synthesis are also discussed. 
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1. Introduction 
Zidovudine (AZT; 3'-azido-2',3'-deoxythymidine), an 
analog of 2'-deoxythymidine, is clinically used to inhibit 
multiplication of human immunodeficiency virus (HIV) in 
patients with acquired immunodeficiency syndrome (AIDS) 
[1-4]. However, long-tema therapy is associated with drug 
toxicity [3,5] and the emergence of AZT-resistant HIV 
mutants [6,7]. In vitro, long-term AZT exposure of a 
human T-cell lymphoma cell line (H 9) increased thymi- 
dine kinase activity. These cells exhibited decreased 
thymidine salvage, AZT salvage, and DNA synthesis [8,9]. 
AZT is known to disturb cellular nucleotide pool [10,11], 
which may consequently affect purine and pyrimidine 
biosynthetic pathways. Since there is no previous report on 
AZT's effect on nucleotide synthetic pathways, we have 
examined the effect of long-term AZT exposure on salvage 
and de novo purine and pyrimidine nucleotide syntheses. A 
preliminary report of this work was presented elsewhere 
[12]. 
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2. Materials and methods 
2.1. Chemicals 
14C-labeled sodium formate (56.6 mCi/mmol) and 
sodium bicarbonate (8.7 mCi/mmol), [5,6-3H]uridine (45 
Ci/mmol) and [8-3H]hypoxanthine (29 Ci/mmol) were 
purchased from ICN Radiochemicals, Irvine, CA. AZT 
was a gift from Burroughs Wellcome, Research Triangle 
Park, NC. Other reagents were of the highest purity avail- 
able from commercial sources. 
2.2. Cell maintenance 
H 9 and H9.AZ T cells were maintained as described 
earlier [8,9]. In brief, the cells were cultured in RPMI 1640 
medium containing 10% heat-inactivated fetal bovine 
serum, penicillin (100 unit/ml) and streptomycin (100 
/~g/ml) at 37°C in a humidified 5% CO2-95% air atmo- 
sphere, n 9 cells grown for 2-6 months in a medium 
containing 25 /~M AZT are referred to as 'long-term AZT 
exposed cells' and called H9.AZ T cells. 
2.3. Hypoxanthine and uridine salvage 
Triplicate samples of exponentially growing cells (1.0 
X l06 cells/ml; 2 ml each) were incubated at 37°C with 
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100 /xM of radiolabeled hypoxanthine or uridine (1 
/~Ci/ml). When the effect of formate on hypoxanthine 
salvage or the effect of sodium bicarbonate on uridine 
salvage was investigated 1.5 mM of sodium formate or 1.5 
mM sodium bicarbonate was also included in the culture 
medium. After a 2-h incubation, the cells were harvested 
by centrifugation (2000 rpm, 10 min, 25 ° C) and washed 
twice with 5 ml of cold phosphate-buffered saline (PBS) to 
remove any unincorporated precursors. The cell pellets 
were then extracted overnight at - 20 ° C with 1 ml of 65% 
methanol. The extract was collected by centrifugation, the 
precipitate washed once with 0.5 ml of ice-cold 65% 
methanol, and the washing was collected with the corre- 
sponding extract. The combined extracts and washing were 
referred to as the methanol 'soluble' fraction and the 
residue as the methanol 'insoluble' fraction. 
Total radioactivity in the methanol 'soluble' and 'in- 
soluble' fractions was determined in a Beckman LSC 5000 
liquid scintillation counter. For this purpose 25-50 /zl of 
the soluble fraction or 0.2 ml of the insoluble fraction 
(solubilized in 0.5 ml of 0.5 N NaOH and neutralized by 
HC1) was mixed with 10 ml of Universol iquid scintilla- 
tion fluid (ICN Radiochemical, Irvine, CA) and counted 
[9]. 
2.4. Purine and pyrimidine de novo synthesis 
Purine and pyrimidine de novo syntheses were assessed 
by following the flux of [znc]formate and [laC]bi- 
carbonate. Triplicate cell suspensions (about 1.0. 10 6 
cells/ml; 2.0 ml each) were incubated with 1.5 mM 
labeled formate or bicarbonate (0.5 /~Ci/ml). In those 
experiments where the incorporation or effect of bicarbon- 
ate were examined, a bicarbonate-free RPMI 1640 was 
used. After 2 h of incubation, cells were washed twice 
with PBS, extracted with 65% methanol, and analyzed as 
described above. 
2.5. Comparison of methanol and perchloric acid nu- 
cleotide extraction methods 
In order to examine whether the methanol extraction 
method used above was adequate for the complete recov- 
ery of nucleotides, this procedure was compared with 
perchloric acid (PCA) extraction followed by neutraliza- 
tion with KOH or trioctylamine. Duplicate H 9 cell suspen- 
sions (about 1. 10 6 cells/ml) were harvested by centrif- 
ugation and washed twice with PBS. The cell pellets were 
extracted either with methanol as described above or with 
PCA. 
For PCA extraction, 100 /xl of 0.5 N PCA solution was 
added to the pellet, vortexed, and allowed to stand on ice 
for 15 min. The supernatant was neutralized either with 10 
/zl 5 N KOH using 2 /.tl Phenol red as an indicator or with 
100 /xl of 0.5 N trioctylamine in 1,1,2-trichlorotrifluoro- 
ethane. After vortexing, the mixture was centrifuged, top 
layer collected, and an aliquot of the extract was analyzed 
by HPLC as described below. 
2.6. HPLC analysis 
To identify nucleotides, aliquots of the methanol ex- 
tracts were dried in a Speed-Vac and reconstituted in 0.1 
ml of HPLC grade water. Fifty microliter samples were 
injected into an HPLC (Bio-Rad) equipped with a Partisil- 
10 SAX column (4.5. 250 mm), equilibrated, and devel- 
oped for 5 min at a flow rate of 1.5 ml/min with solution 
A (0.06 M NH4H2PO 4 containing 10% acetonitrile, v/v) ,  
followed by a linear gradient of 80% of solution B (0.75 M 
NH4H2PO 4 containing 10% acetonitrile) over the next 20 
min and maintaining the final gradient for 5 rain. The 
eluate was monitored at 254 nm with 1.5-ml samples being 
collected and counted for radioactivity. 
3. Results 
3.1. Comparison of nucleotide xtraction methods 
HPLC profiles of a standard nucleotide mixture and H 9 
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Fig. 1. Ion exchange (Partisil-10 SAX) HPLC elution profiles of a 
nucleotide mixture and PCA and methanol extracts of H 9 cells (about 
1-106 cells). The conditions of nucleotide xtraction and chromatography 
are described in Section 2. The eluents were monitored at 254 nm at a full 
scale absorbanee of 0.04. 
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Table 1 
Hypoxanthine and uridine salvage in H 9 and Hg_AZ. r cells 
225 
H 9 cells Hg_AZ T cells H9.AzT/H9 
(mol/106 cells/2 h) (mol/106 cells/2 h) 
[3H]Hypoxanthine (n = 9) 889 4- 540 1003 4- 515 1.18 5:0.2 a 
(P  = 0.82) (P  = 0.016) 
27.4 4- 10 27 4- 6 
227 + 166 
25.4 + 5.9 
'Insoluble' fraction 
(% of total) 
[3H]Uridine (n = 8) 294 4- 207 1.27 4- 0.32 a 
(P  = 0.49) (P  = 0.02) 
'Insoluble' fraction 26.1 4- 8.0 
(% of total) 
Triplicate samples of cells in RPMI-1640 (about 1 • 106 cells/ml; 2 ml) were incubated at 37 ° C for 2 h with 100 /xM labeled hypoxanthine or uridine. 
After incubation the cells were harvested, washed, and extracted with 65% methanol at - 20 ° C. Methanol 'soluble' and 'insoluble' fractions were counted 
for radioactivity. 
a Significantly different from H~ cells. 
obtained by the PCA or methanol extraction were virtually 
superimposable (Fig. 1B). The large peak seen in the PCA 
extract at approximately 4 rain was due to Phenol red 
present in these samples. Compared to PCA extracts, the 
nucleotide peaks in methanol extracts were: UDP, 100%; 
CDP, 91%; ADP, 153%; GDP, 110%; UTP, 108%; CTP, 
113%; ATP, 96%; and GTP 109%. Although a comparison 
of monophosphate p aks was difficult due to their close 
retention times, the total of the peak areas of the methanol 
extract was 110% that of the PCA extract. Thus, the 
methanol extraction used in the present study was slightly 
better than or comparable to PCA extraction. 
3.2. Hypoxanthine and uridine salvage 
The rates of hypoxanthine salvage ranged from 387- 
2112 and 419-1905 with mean values of 889 + 540 and 
1003 + 515 pmol/106 cells/2 h in H 9 and H9_AZ T cells, 
respectively (Table 1). H9_AZ T cells incorporated about 
18% more hypoxanthine than H 9 cells with a mean ratio 
(H9_AZT//H9 cells) of incorporation of 1.18_ 0.2 (P  = 
0.016). There was no difference in the distribution of the 
salvaged hypoxanthine between the 'soluble' (73%) and 
'insoluble' fractions (27%) in H 9 and H9_AZ T cells, sug- 
gesting that the increased hypoxanthine salvaged in H9.AZ T 
cells was evenly distributed between 'soluble' and 'insolu- 
ble' fractions. 
The mean values for the total uridine salvaged were 
227 +_ 166 and 294 _ 207 pmol/106 cells/2 h in H 9 and 
H9.AZ T cells, respectively (Table 1). H9_AZ T cells salvaged 
27% more uridine than H 9 cells with a mean ratio 
(H9_AZT//H9) of 1.27 + 0.32 (P  = 0.02). Of the total uri- 
dine salvaged, 34-38% appeared in the 'insoluble' frac- 
tion. Like hypoxanthine, the increased salvaged uridine in 
H9.AZ T cells was equally distributed in both the soluble 
and insoluble fractions. Although H9.AZ T cells generally 
salvaged more hypoxanthine and uridine, due to large 
interexperimental variations, the mean values of the total 
Table 2 
Incorporation of radioactive precursors of purine and pyrimidine de novo synthesis in H 9 and Hg.AZ T cells 
H 9 cells Hg_Az T cells H9_AzT/H 9 
(pmol/106 cells/2 h) (pmol/106 cells/2 h) 
Purine synthesis 
[14 C]Formate (n = 7) 
'Insoluble' fraction 
(% of total) 
Pyrimidine synthesis 
[14C]Bicarbonate (n = 6) 
'Insoluble' fraction 
(% of total) 
2498 + 1276 2883_ 1091 1.26 4- 0.35 a 
(P  = 0.56) (P  = 0.07) 
28.7 4- 8.8 29.9 4- 10.2 
3116 + 1995 3484 _+ 696 1.38 4- 0.52 
(P  = 0.63) (P  ~ 0.1) 
37.7 + 11.6 34.1 +9.6 
To triplicate cell suspensions in RPMI 1640 (about 1.0- 106 cells/ml; 2 ml) labeled precursors were added at 1.5 mM (bicarbonate-free RPMI 1640 was 
used for pyrimidine synthesis). After 2 h of incubation at 37 ° C, the cells were harvested, washed, and extracted with 65% methanol at - 20 ° C. The 
'soluble' and 'insoluble' fractions were counted for radioactivity. 
a Significantly different from H 9 cells. 
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Table 3 
Distribution of purine and pyrimidine precursors in the nucleotide pool of 
H 9 and Hg_AZ T cells 
Monophosphate Diphosphate Triphosphates 
(Percent of total radioactivity in soluble fraction a) 
Hypoxanthine 
H 9 cells 17 22 61.5 
H9_AZ T cells 18 24.5 57.0 
Formate 
H 9 cells 56.5 9.0 32.6 
H9_AZ T cells 61.1 7.6 30.7 
Uridine 
H 9 cells 51.5 14.7 33.1 
H9_AZ T cells 68.0 11.9 22.3 
Bicarbonate 
H 9 cells 58.6 9.0 33.1 
H9_AZ T cells 61.0 12.2 26.7 
a Average of two experiments. 
nucleoside salvaged were not significantly different (P, 
0.49-0.86). However, the ratios of the incorporation be- 
tween H9_AZ T and H 9 cells were more stable and signifi- 
cantly different. 
3.3. Purine and pyrimidine de novo synthesis 
[14C]Formate and [t4C]bicarbonate incorporation into 
H 9 and H9_AZ T cells is presented in Table 2. Formate 
incorporation i H 9 and H9_AZ T cells was 2498 _+ 1272 and 
2883_ 1091 pmol/106 cells/2 h, respectively, with an 
average ratio (H9_AZ.r/H 9) of 1.26 _+ 0.35 (P  = 0.07). The 
distribution of formate in the 'soluble' fraction (70-71%) 
and in the 'insoluble' fraction (29-30%) was similar in 
both H 9 and H9_AZ T cells. The mean values of bicarbonate 
incorporation were 3116 + 1995 and 3484 _ 696 
pmoles/106 cells/2 h in H 9 and H9.AZ T cells, respec- 
tively, with a H9.AzT /H  9 ratio of 1.38 _+ 0.52 (P  = 0.1). 
Although there was an increase in bicarbonate incorpora- 
tion in Hg_Az v cells, it was not significant. The distribution 
of bicarbonate in 'soluble' fractions (62-66%) and in 
'insoluble' fractions (46%) was similar in both cell lines. 
Table 5 
Effect of hypoxanthine on [14C]formate incorporation and effect of 
formate on [3H]hypoxanthine i corporation i H 9 and H9_AZ T cells, a 
H 9 cells H9_AZ T cells 
(Percent) (Percent) 
[ 14 C]Formate 100 100 
+Hypoxanthine (100/zM) 29_+0.8 * 21 +0.1 * 
[ 3 H]Hypoxanthine 100 100 
+ Formate (1.5 mM) 77 _+ 14 107 _+ 10 
a Values are mean + S.D. of two experiments. 
• P < 0.05. 
3.4. Distribution of the precursors in the nucleotide pool 
The distribution of purine and pyrimidine precursors in 
the nucleotide pool of H 9 and H9_AZ T cells is shown in 
Table 3. The radioactivity from hypoxanthine and formate 
was distributed in adenine and guanine nucleotides, 
whereas uridine and bicarbonate appeared in uridine and 
cytosine nucleotides. The distribution pattern in H 9 and 
H9_AZ T cells was similar. 
3.5. Effect of uridine on bicarbonate incorporation and 
effect of bicarbonate on uridine salvage 
The presence of uridine (100 /~M) reduced bicarbonate 
incorporation (pyrimidine de novo synthesis) to 76 _+ 
19.3% and 77 + 13.9% (P  < 0.05) of control in H 9 and 
H9_AZ T cells, respectively. On the other hand 1.5 mM 
sodium bicarbonate had no effect on uridine salvage (Ta- 
ble 4). 
3.6. Effect of formate on hypoxanthine salvage and effect 
of hypoxanthine on formate incorporation (purine de novo 
synthesis) 
Inclusion of 100 /zM hypoxanthine in the medium 
reduced [14C]formate incorporation to 29 +__ 0.8% and 21 
+ 0.1% of controls (P  < 0.05) in both H 9 and H9_AZ T 
cells, respectively (Table 5). Moreover, 1.5 mM formate 
had no significant effect on [3H]hypoxanthine salvage in 
either cell line. 
Table 4 
Effect of uridine on [J4C]sodium bicarbonate incorporation and effect of 
bicarbonate on [3H]uridine incorporation i H a and H9_AZ T cells a 
H 9 cells H9.AZ T cells 
(Percent) (Percent) 
[ 14 C ]Bicarbonate 100 100 
+ Uridine (100/.tM) 76+ 19 * 77+ 14 * 
13 H]Uridine 100 100 
+Bicarbonate (1.5 raM) 97-1-4 86+ 10 
a Values are mean + S.D. of two experiments. 
* P < 0.05. 
3.7. Effect of short-term AZT exposure of H 9 cells on 
purine and pyrimidine salvage and de novo synthesis 
In order to examine whether a short term exposure of 
cells had any effect on the salvage and/or de novo 
synthes is ,  H 9 cells were treated with 10, 25, and 100 /xM 
AZT for 4 h, washed with PBS, and then examined for the 
incorporation of precursors. Although the data is not pre- 
sented here, short-term exposure of H 9 cells to AZT at 
concentrations up to 100/zM had no effect on the incorpo- 
ration of hypoxanthine, uridine, formate, or bicarbonate. 
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4. Discussion 
These studies demonstrate hat H 9 and H9_AZ T cells are 
capable of actively synthesizing purine and pyrimidine 
nucleotides through 'salvage' and de novo pathways. 
However, variations in the rates of synthesis in day-to-day 
experiments made their comparison difficult. Considering 
the fact that these pathways are highly regulated by a 
number of factors difficult to control [13], the observed 
interexperimental v riations were not surprising. Neverthe- 
less, by conducting experiments simultaneously some of 
the variables were minimized, fluctuations reduced, and a 
definite pattern of changes between H 9 and H9.AZ T cells 
emerged. These observations led us to conclude that only 
those data should be compared which were obtained in 
simultanously run experiments and that the ratios of the 
rates rather than the absolute rates of nucleotide synthesis 
serve a better parameter for comparison. 
The increase in hypoxanthine and uridine salvage in 
H9_AZ T cells was significant. A number of factors could be 
considered to explain this increase: (1) Since nucleotide 
synthesis is elevated in the S phase of the cell cycle, the 
observed increase in nucleotide synthesis in H9.AZ T cells 
may be due to the accumulation of cells in the S-phase of 
cell cycle. However, a sinfilar cell cycle distribution of H 9 
and H9_AZ w cells (data not presented here) ruled this out as 
a possibility. (2) Cellular nucleotide concentrations are 
known to affect the nucleotide synthetic pathways and 
AZT has been shown to disturb cellular nucleotide concen- 
trations [10,11]. It was likely that long-term AZT exposure 
could have induced alterations in the H9_AZ T nucleotide 
pool. However, HPLC p:rofiles of H 9 and H9_AZ T cells 
observed in these studies (not shown here) failed to indi- 
cate any difference in the; nucleotide levels of these cell 
lines. (3) The ineffectiveness of short-term exposure (4 h) 
of cells to AZT, at concentrations a high as 100 /xM, 
suggested that mere accumulation of AZT metabolites 
during short-term exposure [9] was insufficient o alter 
nucleotide synthesis. Although the exact mechanism is 
unclear, it appears that ti~e expression of factors which 
effect nucleotide synthesis requires long-term drug expo- 
sure. To this effect, our recent observations of chromoso- 
mal aberrations and mitoclaondrial damage in H9_AZ T cells 
that occur without a dramatic effect on mitotic index or 
cell viability are important [14]. AZT's carcinogenicity, 
mutagenicity, and incorporation i DNA [14-16] may alter 
the requirement for nucleotides and as a consequence alter 
nucleotide biosynthesis. Thus, the effects on the salvage 
pathway in H9_AZ T cells may reflect AZT-induced changes 
at the genomic level. 
There are a number of reports which indicate that the 
salvage pathway is the primary mechanism of nucleotide 
synthesis in lymphocytes [17-20]. In the current study, 
several-fold more incorporation of formate and bicarbonate 
than hypoxanthine and uridine (Tables 1 and 2) implicates 
that it is the de novo rather than the salvage pathway that 
is the preferred mechanism of nucleotide synthesis in these 
cells. This paradoxical observation may be explained as 
follows. (1) On the molar basis, 2 moles of formate are 
required for the formation of 1 mole of purine. (2) In 
addition to purines, the formate is also incorporated into 
thymine [21], and the bicarbonate may be incorporated in
components other than pyrimidines. (3) A limited avail- 
ability of preformed purines and pyrimidines in the cell 
culture media forces the cells to depend on de novo 
synthesis for their nucleotide requirements that are needed 
for a wide variety of cellular functions. In vivo, however, a
continuous upply of purines and pyrimidines from circu- 
lating blood would fulfill this need. This argument is 
supported by the observation that a significant reduction of 
[14C]formate and bicarbonate incorporation occurs when 
the medium is supplemented with hypoxanthine and uri- 
dine, respectively, as shown in Tables 4 and 5, and re- 
ported elsewhere [22]. Hence, these observations and the 
failure of formate and bicarbonate to affect the hypoxan- 
thine and uridine salvage are consistent with earlier eports 
that the salvage pathway becomes the major route for 
nucleotide synthesis in human lymphocytes, provided pre- 
formed purines and pyrimidines are available. 
Reports of increased nucleotide levels in the lympho- 
cytes of HIV-1 seropositive patients [23] and our observa- 
tions of accelerated nucleotide syntheses in AZT-treated 
cells suggest that further studies on nucleotide synthesis in 
lymphocytes from HIV patients who are on long term AZT 
therapy are needed. Such studies may provide insight into 
the mechanisms of virus- and AZT-induced perturbations 
in nucleotide biosynthesis and a new perspective for 
chemotherapeutic approaches of AZT and other antiviral 
nucleosides currently under consideration for HIV chemo- 
therapy. 
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